Patents by Inventor Thibaut DOUCHE

Thibaut DOUCHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marker for predicting the sensitivity to PI3K inhibitors
    Patent number: 12000833
    Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: June 4, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Julie Guillermet-Guibert, Thibaut Douche, Emmanuelle Mouton-Barbosa, Odile Schiltz, Marie-Pierre Bousquet, Célia Cintas
  • A NEW MARKER FOR PREDICTING THE SENSITIVITY TO PI3K INHIBITORS
    Publication number: 20200355693
    Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.
    Type: Application
    Filed: November 22, 2018
    Publication date: November 12, 2020
    Inventors: Julie GUILLERMET-GUIBERT, Thibaut DOUCHE, Emmanuelle MOUTON-BARBOSA, Odile SCHILTZ, Marie-Pierre BOUSQUET, Célia CINTAS